Detail akcie Waverley Pharma Rg online

Business Summary: Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development and commercialization of human therapeutics focused on oncology. It is advancing its PARP-1 pre-clinical development program, which is in the lead optimization stage, in response to the interest in novel PARP-1 inhibitors that demonstrate selective activity against PARP-1 over PARP-2. The lead compound exhibits single-digit nanomolar activity and significant selectivity for PARP-1 over PARP-2, in pre-clinical invitro testing. It has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited (Licensor or RLS) by which the Licensor granted the Company an exclusive territorial license to market and sell capecitabine in the United Kingdom (UK) and Germany as well as a non-exclusive territorial license to market and sell temozolomide in the UK. It also has territorial licenses from RLS to two oncologic drugs, pemetrexed and bortezomib.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Waverley Pharma Inc revenues increased from C$22K to C$1.1M. Net loss decreased 66% to C$302K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Biopharmaceutical company segment loss decrease of 74% to C$198K. Basic Earnings per Share excluding Extraordinary Items increased from -C$0.02 to -C$0.01.